Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
BMJ Open Gastroenterol
; 7(1)2020 09.
Article
en En
| MEDLINE
| ID: mdl-32912846
ABSTRACT
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Colangitis Esclerosante
/
Adenocarcinoma del Pulmón
/
Nivolumab
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
BMJ Open Gastroenterol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Australia